AMT-253 in Patients With Advanced Solid Tumours

This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.

Trial Details

NCT ID
NCT06209580
Phase
PHASE1 / PHASE2
Sponsor
Multitude Therapeutics Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • AMT-253 for injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • 1\. Patients must be willing and able to understand and sign the ICF, and to adhere to the study visit schedule and other protocol requirements.
  • 2\. Patients with histologically confirmed melanoma or other advanced solid tumor.
  • 3\. Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease (PD) during or a…
  • 4\. Patients must have at least one measurable lesion as per RECIST version 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →